Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

It is a CAR-T (chimeric antigen receptor T-cell) therapy, where a patient’s ... a proteasome inhibitor and an anti-CD38 antibody such as Janssen’s Darzalex (daratumumab).

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

The bispecific antibody targets GPRC5D – which is overexpressed on myeloma cells ... which includes CD38 antibody Darzalex (daratumumab) and two BCMA-targeting therapies, CAR-T Carvykti ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

A new part of an ocean plant cell has been discovered that might revolutionize farming one day. The structure can take ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...